Is there a Bearish outlook for Bristol-Myers Squibb Company (NYSE:BMY) this week?

October 13, 2018 - By Clifton Ray

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.78 in 2018 Q2. Its down 0.05, from 0.83 in 2018Q1. It worsened, as 94 investors sold Bristol-Myers Squibb Company shares while 550 reduced holdings. 108 funds opened positions while 396 raised stakes. 1.14 billion shares or 1.65% more from 1.12 billion shares in 2018Q1 were reported.
State Treasurer State Of Michigan accumulated 0.33% or 750,617 shares. Hills Comml Bank & Tru owns 0.36% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 22,537 shares. Jpmorgan Chase And reported 0.26% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Klingenstein Fields & Lc holds 63,273 shares. Princeton Port Strategies Grp Incorporated Limited Liability Com owns 37,327 shares. Wesbanco Bank & Trust reported 474,406 shares. Twin Cap Incorporated has 0.55% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 197,080 shares. Conning Incorporated holds 0.18% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 107,769 shares. Kistler owns 0.32% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 13,081 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 374,296 shares. Moreover, Institute For Wealth Mngmt Ltd Liability Co has 0.34% invested in Bristol-Myers Squibb Company (NYSE:BMY). M Securities stated it has 0.5% in Bristol-Myers Squibb Company (NYSE:BMY). Dixon Hubard Feinour And Brown Va has invested 1.02% in Bristol-Myers Squibb Company (NYSE:BMY). Madison Inv reported 4,774 shares. Jnba Financial Advsr holds 0.03% or 2,902 shares in its portfolio.

Since April 30, 2018, it had 1 buy, and 0 sales for $249,948 activity.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 10 analysts covering Bristol-Myers Squibb (NYSE:BMY), 2 have Buy rating, 0 Sell and 8 Hold. Therefore 20% are positive. Bristol-Myers Squibb had 13 analyst reports since April 17, 2018 according to SRatingsIntel. The stock has “Neutral” rating by Atlantic Securities on Wednesday, August 8. As per Wednesday, April 18, the company rating was maintained by BMO Capital Markets. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Overweight” rating given on Monday, October 8 by JP Morgan. Credit Suisse maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Friday, July 27. Credit Suisse has “Neutral” rating and $61 target. The stock has “Market Perform” rating by BMO Capital Markets on Friday, April 27. Guggenheim maintained the stock with “Buy” rating in Tuesday, April 17 report. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Equal-Weight” rating by Barclays Capital on Friday, October 12. UBS downgraded the shares of BMY in report on Monday, May 21 to “Hold” rating. Bank of America maintained it with “Neutral” rating and $61 target in Tuesday, April 17 report. Morgan Stanley downgraded Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday, April 17 to “Equal-Weight” rating. Below is a list of Bristol-Myers Squibb Company (NYSE:BMY) latest ratings and price target changes.

12/10/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $55 New Target: $58 Maintain
08/10/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $70 New Target: $74 Maintain
08/08/2018 Broker: Atlantic Securities Old Rating: Underweight New Rating: Neutral Old Target: $57 Upgrade
27/07/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Neutral Old Target: $58 New Target: $61 Maintain
23/07/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $47 New Target: $51 Maintain
21/05/2018 Broker: UBS Rating: Hold New Target: $57.0000 Downgrade
26/04/2018 Broker: Barclays Capital Rating: Hold New Target: $55.0000
27/04/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Market Perform Old Target: $47 Upgrade
20/04/2018 Broker: Cowen & Co Rating: Hold New Target: $60.0000 Maintain
18/04/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Underperform Old Target: $51 New Target: $47 Maintain

The stock increased 0.02% or $0.01 during the last trading session, reaching $57.51. About 10.71M shares traded or 88.59% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 4.27% since October 13, 2017 and is downtrending. It has underperformed by 19.89% the S&P500.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $93.85 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 255.6 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

More recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers Squibb’s Opdivo flunks late-stage lung cancer study” on October 12, 2018. Also Seekingalpha.com published the news titled: “Compugen up 18% premarket on collaboration with Bristol-Myers Squibb team in study of doublet therapy in solid tumors” on October 11, 2018. Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: October 09, 2018 was also an interesting one.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>